Stoke Therapeutics chief medical officer Barry Ticho sold 14,311 shares of common stock for approximately $457,000 between 17 March and 19 March 2026, according to an SEC Form 4 filing. The sale price averaged $31.92 per share. The transaction reduced Ticho's direct holdings from 55,013 to 40,702 shares, a 26% decrease. He retains 83,035 stock options, giving him total beneficial interest of approximately 123,700 shares. The sale, which involved exercising options followed by immediate disposal, exceeded Ticho's historical median sale size of 7,073 shares. It occurred following a 300% one-year share price increase for the biotechnology company, which develops treatments for rare genetic neurological disorders. Stoke Therapeutics has a market capitalisation of $1.98 billion.

Stoke Therapeutics and Biogen announced that data on investigational Dravet syndrome treatment zorevunersen were published in The New England Journal of Medicine, showing multi-year seizure reductions and cognitive improvements. The company also updated its Phase 3 EMPEROR timeline, with enrollment completing by Q2 2026, mid-2027 readout, and plans to begin rolling FDA submission in the first half of 2027. The NEJM publication strengthens the biological rationale for zorevunersen's antisense platform. However, the key near-term catalyst remains whether the Phase 3 trial can confirm the long-term seizure and cognitive benefits observed thus far. Stoke's narrative projects $81.1 million revenue and $13.2 million earnings by 2028, implying a 26.7% yearly revenue decline. Optimistic analysts model 2028 revenue near $63.4 million.

Stoke Therapeutics to present at the Guggenheim Emerging Outlook: Biotech Summit 2026. Provided By Business Wire - Last update: Feb 4, 2026 Article Mentions: Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 2:30 p.m. ET. A live audio webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Stoke Therapeutics Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke's proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/. About Zorevunersen Zorevunersen is an investigational antisense oligonucleotide that is designed to treat the underlying cause of Dravet syndrome by increasing functional NaV1.1 protein production in brain cells from the non-mutated (wild-type) copy of the SCN1A gene. This highly differentiated mechanism of action aims to reduce seizure frequency beyond what has been achieved with anti-seizure medicines and to improve neurodevelopment, cognition and behavior. Zorevunersen has demonstrated the potential for disease modification and has been granted orphan drug designation by the FDA and the EMA. The FDA has also granted zorevunersen rare pediatric disease designation and Breakthrough Therapy Designation for the treatment of Dravet syndrome with a confirmed mutation not associated with gain-of-function, in the SCN1A gene. Stoke has a strategic collaboration with Biogen (Nasdaq: BIIB) to develop and commercialize zorevunersen for Dravet syndrome. Under the collaboration, Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights.